Sperm DNA fragmentation levels in testicular sperm samples from azoospermic males as assessed by the sperm chromatin dispersion (SCD) test
Objective
To analyze sperm DNA fragmentation (SDF) in testicular sperm samples from patients with azoospermia either from spermatogenic failure or from duct obstruction. Several technologies can be applied in the evaluation of SDF, but given the ease and low costs, the sperm chromatin dispersion test (SCD) has emerged as a promising standard.
Design
Prospective blind observational cohort study.
Setting
University-affiliated private IVF setting.
Patient(s)
Azoospermic patients from couples undergoing intracytoplasmic sperm injection cycles.
Intervention(s)
Testicular sperm extraction (TESE).
Main Outcome Measurement(s)
We determined testicular SDF, and a basic comparison between nonobstructive (n = 22) and obstructive azoospermia (n = 40) was performed. We also correlated SDF with embryo quality and pregnancy outcome.
Result(s)
SDF in the testicular sperm of patients with nonobstructive azoospermia was significantly higher, 46.92% (SEM = 4.47), than that of patients with obstructive azoospermia, 35.96% (SEM = 2.63). A moderate relationship between embryo morphology and testicular SDF was detected. Logistic regression analysis of the effect of testicular SDF on pregnancy outcome revealed no significant effect (odds ratio = 1.015).
Conclusion(s)
Ours is the first report of SDF analysis in testicular sperm by using SCD in azoospermia. This result suggests that spermatogenesis failure may result in a severe affectation of sperm DNA integrity. The degree of DNA fragmentation using the SCD test is not reflected in pregnancy chances, and the explanation could be that embryos have been selected.
Key Words: Testicular sperm, DNA fragmentation, spermatogenesis, embryo quality, SCD test
To access this article, please choose from the options below
M.M. has nothing to disclose. R.S. has nothing to disclose. N.G. has nothing to disclose. M.G.-S. has nothing to disclose. J.R. has nothing to disclose. J.L.F. has nothing to disclose.
This work was presented in part at the 33rd meeting of the American Society of Andrology, Albuquerque, NM, April 2008.
This work was supported by IMPIVA IMIDTF/2007/182 (Generalitat Valenciana) and Xunta de Galicia INCITE07PXI916201ES.
PII: S0015-0282(08)03727-8
doi:10.1016/j.fertnstert.2008.08.106
© 2009 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.

